112 related articles for article (PubMed ID: 8924251)
1. Syncytium-inducing phenotype and zidovudine susceptibility of HIV-1 isolated from post-mortem tissue.
McGavin CH; Land SA; Sebire KL; Hooker DJ; Gurusinghe AD; Birch CJ
AIDS; 1996 Jan; 10(1):47-53. PubMed ID: 8924251
[TBL] [Abstract][Full Text] [Related]
2. Additional mutations detected in sequential HIV-1 isolates from ZDV-treated patients.
Magierowska-Jung M; Agut H; Katlama C; Autran B; Huraux JM
J Med Virol; 1997 Jan; 51(1):48-55. PubMed ID: 8986949
[TBL] [Abstract][Full Text] [Related]
3. Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients.
Kuritzkes DR; Quinn JB; Benoit SL; Shugarts DL; Griffin A; Bakhtiari M; Poticha D; Eron JJ; Fallon MA; Rubin M
AIDS; 1996 Aug; 10(9):975-81. PubMed ID: 8853730
[TBL] [Abstract][Full Text] [Related]
4. Quantitative differences in the distribution of zidovudine resistance mutations in multiple post-mortem tissues from AIDS patients.
Atkins M; Strappe P; Kaye S; Loveday C; McLaughlin JE; Johnson MA; Tedder RS; Griffiths PD; Emery VC
J Med Virol; 1998 Jun; 55(2):138-46. PubMed ID: 9598935
[TBL] [Abstract][Full Text] [Related]
5. Zidovudine susceptibility testing of human immunodeficiency virus type 1 (HIV) clinical isolates.
Shafer RW; Kozal MJ; Katzenstein DA; Lipil WH; Johnstone IF; Merigan TC
J Virol Methods; 1993 Mar; 41(3):297-310. PubMed ID: 8097199
[TBL] [Abstract][Full Text] [Related]
6. Characterization of HIV isolates arising after prolonged zidovudine therapy.
Mayers DL; McCutchan FE; Sanders-Buell EE; Merritt LI; Dilworth S; Fowler AK; Marks CA; Ruiz NM; Richman DD; Roberts CR
J Acquir Immune Defic Syndr (1988); 1992; 5(8):749-59. PubMed ID: 1381438
[TBL] [Abstract][Full Text] [Related]
7. The role of HIV type 1 phenotype and genotype in long-term responders to zidovudine therapy.
Angarano G; Monno L; Vivirito MC; Appice A; Romanelli C; Giannelli A; La Grasta L; Fracasso C; Fiore JR; Milazzo F
AIDS Res Hum Retroviruses; 1996 Jul; 12(11):969-75. PubMed ID: 8827212
[TBL] [Abstract][Full Text] [Related]
8. Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. The RV-43 Study Group, the AIDS Clinical Trials Group Virology Committee Resistance Working Group.
Japour AJ; Mayers DL; Johnson VA; Kuritzkes DR; Beckett LA; Arduino JM; Lane J; Black RJ; Reichelderfer PS; D'Aquila RT
Antimicrob Agents Chemother; 1993 May; 37(5):1095-101. PubMed ID: 8517697
[TBL] [Abstract][Full Text] [Related]
9. Development and significance of zidovudine resistance in children infected with human immunodeficiency virus.
Ogino MT; Dankner WM; Spector SA
J Pediatr; 1993 Jul; 123(1):1-8. PubMed ID: 8100579
[TBL] [Abstract][Full Text] [Related]
10. Comparison of viral burden and phenotype of HIV-1 isolates from lymph nodes and blood.
Tamalet C; Lafeuillade A; Yahi N; Vignoli C; Tourres C; Pellegrino P; de Micco P
AIDS; 1994 Aug; 8(8):1083-8. PubMed ID: 7986403
[TBL] [Abstract][Full Text] [Related]
11. Susceptibility of HIV-1 isolates to zidovudine: correlation between widely applicable culture test and PCR analysis.
Jung M; Agut H; Candotti D; Ingrand D; Katlama C; Huraux JM
J Acquir Immune Defic Syndr (1988); 1992; 5(4):359-64. PubMed ID: 1372352
[TBL] [Abstract][Full Text] [Related]
12. Didanosine (ddI) and zidovudine (ZDV) susceptibilities of human immunodeficiency virus (HIV) isolates from long-term recipients of ddI.
Reichman RC; Tejani N; Lambert JL; Strussenberg J; Bonnez W; Blumberg B; Epstein L; Dolin R
Antiviral Res; 1993 Apr; 20(4):267-77. PubMed ID: 8097906
[TBL] [Abstract][Full Text] [Related]
13. In vivo compartmentalization of human immunodeficiency virus: evidence from the examination of pol sequences from autopsy tissues.
Wong JK; Ignacio CC; Torriani F; Havlir D; Fitch NJ; Richman DD
J Virol; 1997 Mar; 71(3):2059-71. PubMed ID: 9032338
[TBL] [Abstract][Full Text] [Related]
14. Dideoxynucleoside resistance emerges with prolonged zidovudine monotherapy. The RV43 Study Group.
Mayers DL; Japour AJ; Arduino JM; Hammer SM; Reichman R; Wagner KF; Chung R; Lane J; Crumpacker CS; McLeod GX
Antimicrob Agents Chemother; 1994 Feb; 38(2):307-14. PubMed ID: 8192457
[TBL] [Abstract][Full Text] [Related]
15. Long-term intake of Korean red ginseng in HIV-1-infected patients: development of resistance mutation to zidovudine is delayed.
Cho YK; Sung H; Lee HJ; Joo CH; Cho GJ
Int Immunopharmacol; 2001 Jul; 1(7):1295-1305. PubMed ID: 11460310
[TBL] [Abstract][Full Text] [Related]
16. Viral load, viral phenotype modification, zidovudine susceptibility and reverse transcriptase mutations during the first 6 months of zidovudine monotherapy in HIV-1-infected people.
Rusconi S; De Pasquale MP; Mainini F; Bulgheroni E; Kurtagic S; Gori A; Violin M; Zanchetta N; Moroni M; Balotta C; Galli M
Antivir Ther; 1996 Dec; 1(4):211-9. PubMed ID: 11324823
[TBL] [Abstract][Full Text] [Related]
17. Development of resistance of zidovudine (ZDV) and didanosine (ddI) in HIV from patients in ZDV, ddI and alternating ZDV/ddI therapy.
Nielsen C; Bruun L; Mathiesen LR; Pedersen C; Gerstoft J
AIDS; 1996 Jun; 10(6):625-33. PubMed ID: 8780817
[TBL] [Abstract][Full Text] [Related]
18. Reduction of HIV-1 in blood and lymph nodes following potent antiretroviral therapy and the virologic correlates of treatment failure.
Wong JK; Günthard HF; Havlir DV; Zhang ZQ; Haase AT; Ignacio CC; Kwok S; Emini E; Richman DD
Proc Natl Acad Sci U S A; 1997 Nov; 94(23):12574-9. PubMed ID: 9356491
[TBL] [Abstract][Full Text] [Related]
19. Selective vertical transmission of HIV-1 antiretroviral resistance mutations.
Colgrove RC; Pitt J; Chung PH; Welles SL; Japour AJ
AIDS; 1998 Dec; 12(17):2281-8. PubMed ID: 9863870
[TBL] [Abstract][Full Text] [Related]
20. HIV-1 biological phenotype in long-term infected individuals evaluated with an MT-2 cocultivation assay.
Koot M; Vos AH; Keet RP; de Goede RE; Dercksen MW; Terpstra FG; Coutinho RA; Miedema F; Tersmette M
AIDS; 1992 Jan; 6(1):49-54. PubMed ID: 1543566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
